Skip to main content

Table 1 Categorical and continuous variables of patients with different numbers of NLN

From: Number of negative lymph nodes with a positive impact on survival of stage III colon cancer; a retrospective observation study for right side and left side colon

 

Right side colon, n = 891

 

Left side colon, n = 1353

Categorical variables

NLN ≥ 27

n = 499

(100%)

NLN <  27

n = 392(100%)

NLN ≥ 12

n = 1020

(100%)

NLN <  12

n = 333

(100%)

Sex, P-value

0.069

 

0.254

 

 Male

219 (43.9)

196 (50.0)

530 (52.0)

185 (55.6)

 Female

280 (56.1)

196 (50.0)

490 (48.0)

148 (44.4)

Age, P-value

0.001

 

0.002

 

 Mean, SD (years)

62.2, ±13.5

65.2, ±13.6

61.5, ±13.4

64.1, ±12.8

Age groups, P-value

0.004

 

0.010

 

 < 50 year-old

86 (17.2)

53 (13.5)

185 (18.1)

44 (13.2)

 50–65 year-old

188 (37.7)

115 (29.3)

408 (40.0)

116 (34.8)

 65–80 year-old

177 (35.5)

171 (43.6)

339 (33.2)

140 (42.0)

 ≥80 year-old

48 (9.6)

53 (13.5)

88 (8.6)

33 (9.9)

BMIa, P-value

0.184

 

0.226

 

 Mean, SD

23.6, ±3.6

23.9,±3.9

24.2, ±3.7

24.5,±3.7

BMI groupsa, P-value

0.379

 

0.706

 

 Underweight

(BMI < 18.5)

31 (6.2)

24 (6.3)

45 (4.5)

11 (3.4)

 Normal weight

(18.5≦BMI <  24)

260 (52.3)

182 (47.8)

460 (45.5)

142 (44.0)

 Overweight

(24≦BMI <  27)

117 (23.5)

109 (28.6)

292 (28.9)

94 (29.1)

 Obesity

(BMI≧27)

89 (17.9)

66 (17.3)

214 (21.2)

76 (23.5)

Pre-OP CEAa, P-value

0.566

 

0.715

 

 Mean, SD (ng/mL)

11.2, ±24.5

12.3, ±31.5

8.7, ±20.4

9.1, ±19.0

CEA groups, P-value

0.459

 

0.054

 

 ≥5 ng/mL

181 (37.0)

150 (39.5)

339 (33.5)

128 (39.4)

 < 5 ng/mL

308 (63.0)

230 (60.5)

672 (66.5)

197 (60.6)

Pre-OP NLR, P-value

0.219

 

0.007

 

 Mean, SD

3.3, ±2.8

3.6, ±3.9

2.8, ±2.1

3.3, ±3.8

NLR,P-value

0.650

 

0.060

 

 ≥2.87

200 (43.7)

143 (42.1)

284 (30.7)

100 (36.8)

 < 2.87

258 (56.3)

197(57.9)

641 (69.3)

172 (63.2)

Histology type, P-value

0.389

 

0.019

 

 Adenocarcinoma

427 (85.6)

341 (87.0)

966 (94.7)

307 (92.2)

 Signet ring cell

11 (2.2)

4 (1.0)

5 (0.5)

7 (2.1)

 Mucinous

61 (12.2)

47 (12.0)

49 (4.8)

19 (5.7)

Histology grade, P-value

0.028

 

0.771

 

 Well differentiation

28 (5.6)

41 (10.5)

83 (8.1)

29 (8.7)

 Moderate differentiation

379 (76.1)

284 (72.4)

872 (85.6)

279 (84.0)

 Poorly differentiation

91 (18.3)

67 (17.1)

64 (6.3)

24 (7.2)

T stage of TNM, P-value

< 0.001

 

< 0.001

 

 T1

14 (2.8)

1 (0.3)

40 (3.9)

17 (5.1)

 T2

17 (3.4)

17 (4.3)

80 (7.8)

36 (10.8)

 T3

293 (58.7)

179 (45.7)

594 (58.2)

140 (42.0)

 T4

175 (35.1)

195 (49.7)

306 (30.0)

140 (42.0)

N stage of TNM, P-value

0.019

 

0.004

 

 N1

349 (70.1)

245(62.5)

697(68.3)

199(59.8)

 N2

150 (29.9)

147 (37.5)

323 (31.7)

134 (40.2)

 Stage III, P-value

0.045

 

< 0.001

 

 IIIA

32 (5.8)

13 (3.9)

105 (10.3)

42 (12.6)

 IIIB

409 (73.6)

225 (67.2)

720 (70.6)

195 (58.6)

 IIIC

115 (20.7)

97 (29)

195 (19.1)

96 (28.8)

Adjuvant C/T, P-value

< 0.001

 

0.001

 

 Yes

446 (85.4)

242 (74.7)

807 (82.9)

247 (74.6)

 No

76 (14.6)

82 (25.3)

166 (17.1)

84 (25.4)

ELN, P-value

< 0.001

 

< 0.001

 

 Mean, SD

46.5, ±15.2

20.6, ±6.5

30.2, ±13.9

11.4, ±4.3

ELN group, P-value

< 0.001

 

< 0.001

 

 ≥12

556 (100.0)

300 (89.6)

1020 (100.0)

248 (74.5)

PLN, P-value

0.002

 

< 0.001

 

 Mean, SD

3.2, ±3.4

4.0, ±4.3

3.3, ±3.4

4.2, ±4.1

NLN, P-value

< 0.001

 

<  0.001

 

 Mean, SD

43.3, ±14.8

16.6, ±6.0

26.9, ±13.6

7.2, ±2.9

  1. ELN examined lymph node number, NLN negative lymph node number, PLN positive lymph node, BMI body mass index, TNM tumor/node/metastasis classification, N1 of TNM metastasis in 1–3 regional lymph nodes, N2 of TNM metastasis in ≥4 regional lymph nodes, Adjuvant C/T adjuvant chemotherapy, SD standard deviation, CEA carcinoembryonic antigen, NLR neutrophil to lymphocyte ratio
  2. a:missing data; 39 patients in CEA data and 13 patients in BMI data